These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Immunological aspects of melanoma]. Sjögren H Lakartidningen; 1976 Feb; 73(7):528-30. PubMed ID: 1250045 [No Abstract] [Full Text] [Related]
6. Immunoprophylaxis of malignant melanoma with systemic BCG: study of strain, dose, and schedule. Gutterman JU; Mavligit G; McBride C; Frei E; Hersh EM Natl Cancer Inst Monogr; 1973 Dec; 39():205-12. PubMed ID: 4595319 [No Abstract] [Full Text] [Related]
7. [Results in the use of immunochemotherapy in patients with cutaneous malignant melanoma]. Calbo L; Gorgone S; Palmeri R; Salibra M; Melita P Chir Ital; 1983 Aug; 35(4):519-25. PubMed ID: 6680859 [TBL] [Abstract][Full Text] [Related]
9. [BCG-treatment of malignant melanoma]. Borberg H Internist (Berl); 1975 Oct; 16(10):482-5. PubMed ID: 1107254 [No Abstract] [Full Text] [Related]
10. Immunologic defects in melanoma patients: lack of effect of BCG therapy. Gersten MJ; Hadden EM; Kaplan MH; Pinsky CM; Armstrong D; Hadden JW Clin Bull; 1977; 7(2):63-9. PubMed ID: 902403 [No Abstract] [Full Text] [Related]
11. Immunological changes in cancer patients receiving BCG. Cochran AJ; Mackie RM; Jackson AM; Ogg LJ; Ross CE Dev Biol Stand; 1977 Apr 13-15; 38():441-8. PubMed ID: 608535 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-Guérin. MacGregor AB; Falk RE; Landi S; Ambus U; Samuel ES; Langer B Can J Surg; 1977 Jan; 20(1):25-30. PubMed ID: 832200 [TBL] [Abstract][Full Text] [Related]
13. The immune response in human malignant melanoma. Mackie RM Clin Exp Dermatol; 1976 Mar; 1(1):23-8. PubMed ID: 773575 [No Abstract] [Full Text] [Related]
14. [Experience with adjuvant chemoimmunotherapy with DTIC and BCG in malignant melanoma (author's transl)]. Pullmann H; Muth M Z Hautkr; 1982 Feb; 57(4):294-7. PubMed ID: 7080583 [No Abstract] [Full Text] [Related]
15. [Immunologic aspects of the treatment of melanoma]. Pawlowska EM Pol Tyg Lek; 1977 Jun; 32(24):939-41. PubMed ID: 882435 [No Abstract] [Full Text] [Related]
16. [Immune profil in melanoma patients. III. Behavior of immunglobulins (IgG, IgA, IgM) and of whole complement in serum at the beginning and during BCG-therapy (author's transl)]. Knopf B; Wätzig V; Stelzner A Arch Geschwulstforsch; 1979; 49(4):299-304. PubMed ID: 496567 [TBL] [Abstract][Full Text] [Related]
18. Immune response and non-specific immunotherapy in melanoma. El-Domeiri AA Ann R Coll Surg Engl; 1978 Mar; 60(2):117-20. PubMed ID: 637492 [TBL] [Abstract][Full Text] [Related]
19. Results of adjuvant BCG immunotherapy in malignant melanoma. Wätzig V; Knopf B Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442 [TBL] [Abstract][Full Text] [Related]
20. Effects of BCG and Corynebacterium parvum on immune reactivity in melanoma patients. Thatcher N; Crowther D Dev Biol Stand; 1977 Apr 13-15; 38():449-53. PubMed ID: 608536 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]